Colonic dysplasia and cancer in inflammatory bowel disease

Gastrointestinal Endoscopy Clinics of North America

Volumn 12, Issue 3, 2002, Pages 495-523

  Judge, Thomas A ^a   Lewis, James D ^a   Lichtenstein, Gary R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; AZATHIOPRINE; FOLIC ACID; IMMUNOMODULATING AGENT; MESALAZINE; METRONIDAZOLE; MINERAL; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; RETINOL; SALAZOSULFAPYRIDINE; VITAMIN;

CHEMOPROPHYLAXIS; COLON BIOPSY; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE DURATION; DYSPLASIA; ENTERITIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; CROHN DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; RISK FACTORS;

EID: 0036660621     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5157(02)00014-4     Document Type: Review

References (129)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759-67.
2. Podolsky DK. Inflammatory Bowel Disease (2). N Engl J Med 1991;325(14):1008-16.
3. Ahnen DJ. Tissue markers of colon cancer risk. Gastrointest Endosc 1999;49:S50-9.
4. Goh HS, Jass JR. DNA content and the adenoma-carcinaoma sequence in colorectum. J Clin Pathol 1986;39:387-92.
5. Rognum TO, Thorud E, Lund E. Survival of large bowel carcinoma patients with different DNA ploidy. Br J Cancer 1987;56:633-6.
6. Meling GI, Clausen OP, Bergan A, Schjolberg A, Rognum TO. Flow cytometric DNA ploidy pattern in dysplastic mucosa, and in primary and metastatic carcinomas in patients with long-standing ulcerative colitis. Br J Cancer 1991;64(2):339-44.
7. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103(5):1611-20.
8. Souza RF, Lei J, Yin J, Appel R, Zou TT, Zhou X, et al. A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms. Gastroenterology 1997;112(1):40-5.
9. Suzuki H, Harpaz N, Tarmin L, Yin J, Jiang HY, Bell JD, et al. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res 1994;54(18):4841-4.
10. Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio LB, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995;55(10):2035-8.
11. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107(2):369-78.
12. Burmer GC, Crispin DA, Kolli VR, Haggitt RC, Kulander BG, Rubin CE, et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun 1991;3(6):167-72.
13. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993;104(6):1633-9.
14. Willenbucher RF, Zelman SJ, Ferrell LD, Moore DH II, Waldman FM. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 1997;113(3):791-801.
15. Burmer GC, Levine DS, Kulander BG, Haggitt RC, Rubin CE, Rabinovitch PS. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology 1990;99(2):416-20.
16. Chen J, Compton C, Cheng E, Fromowitz F, Viola MV. c-Ki-ras mutations in dysplastic fields and cancers in ulcerative colitis. Gastroenterology 1992;102(6):1983-7.
17. Noffsinger A, Kretschmer S, Belli J, Fogt F, Fenoglio-Preiser C. Microsatellite instability is uncommon in intestinal mucosa of patients with Crohn's disease. Dig Dis Sci 2000;45:378-84.
18. Brostrom O, Lofberg R, Nordenvall B, Ost A, Hellers G. The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand J Gastroenterol 1987;22(10):1193-9.
19. Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971;285(1):17-21.
20. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323(18):1228-33.
21. Gilat T, Fireman Z, Grossman A, Hacohen D, Kadish U, Ron E, et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 1988;94(4):870-7.
22. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease: A comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35(11):1590-2.
23. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, et al. Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from three centres. Gut 1988;29(2):206-17.
24. Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis - Based on results from a regional patient group from the county of Copenhagen. Gut 1985;26(2):158-63.
25. Katzka I, Brody RS, Morris E, Katz S. Assessment of colorectal cancer risk in patients with ulcerative colitis: Experience from a private practice. Gastroenterology 1983;85(1):22-9.
26. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990;31(7):800-6.
27. MacDougall IPM. The cancer risk in ulcerative colitis. Lancet 1964;2:655-58.
28. Mir-Madjlessi SH, Farmer RG, Easley KA, Beck GJ. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer 1986;58(7):1569-74.
29. Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001;120:841-7.
30. Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses Jr. AH, Greenstein AJ. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991;32(2):167-9.
31. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: A case control study. Dis Colon Rectum 1997;40(4):451-6.
32. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110(2):331-8.
33. Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis - A risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102(6):1877-80.
34. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 1995;22(5):1404-8.
35. D'Haens G, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993;88(8):1174-8.
36. Gurbuz AK, Giardiello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 1995;38(1):37-41.
37. Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease [letter]. N Engl J Med 1994;331(13):883-4.
38. Lashner B, Shetty K, Rybicki L, Brzezinski A. Risk factors for cancer or dysplasia in ulcerative colitis with primary sclerosing cholangitis. Gastroenterology 1998;114(4):A1018.
39. Loftus EV Jr, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996;110(2):432-40.
40. Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92(8):1285-8.
41. Rosenstock E, Farmer RG, Petras R, Sivak MV Jr, Rankin GB, Sullivan BH. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985;89(6):1342-6.
42. Ziv Y, Fazio VW, Sirimarco MT, Lavery IC, Goldblum JR, Petras RE. Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum 1994;37(12):1281-5.
43. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994;74(7):1847-54.
44. Broome U, Lofberg R, Lundqvist K, Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum 1995;38(12):1301-5.
45. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994;107(1):117-20.
46. Davis AE, Patterson F, Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br J Cancer 1992;66(5):777-80.
47. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8(12):1179-83.
48. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333(10):609-14.
49. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85(11):912-6.
50. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72(4):1171-7.
51. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325(23):1593-6.
52. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112(1):29-32.
53. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343 (8908):1249-52.
54. Goldstein ES, Marion JF, Wheeler S, Present DH. 6-Mercaptopurine (6-MP): Does it increase or decrease the risks of colon cancer in Crohn's disease. Gastroenterol 1998;114:A986.
55. Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993;119(9):549-54.
56. Halsted CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med 1981;305(25):1513-7.
57. Swinson CM, Perry J, Lumb M, Levi AJ. Role of sulphasalazine in the aetiology of folate deficiency in ulcerative colitis. Gut 1981;22(6):456-61.
58. Willett WC, Hunter DJ. Vitamin A and cancers of the breast, large bowel, and prostate: Epidemiologic evidence. Nutr Rev 1994;52(2 Pt 2):S53-9.
59. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 1998;129:517-24.
60. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
61. Malila N, Virtamo J, Virtanen M, Albanes D, Tangrea JA, Huttunen JK. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. Cancer Epidemiol Biomarkers Prev 1999;8:489-93.
62. Sellers TA, Bazyk AE, Bostick RM, Kushi LH, Olson JE, Anderson KE, Lazovich D, Folsom AR. Diet and risk of colon cancer in a large prospective study of older women: An analysis stratified on family history. Cancer Causes Control 1998;9(4):357-67.
63. Beart RW Jr. J pouch with ileoanal anastomosis. Can J Surg 1987;30(5):361-2.
64. Marcello PW, Roberts PL, Schoetz DJ Jr, Coller JA, Murray JJ, Veidenheimer MC. Long-term results of the ileoanal pouch procedure. Arch Surg 1993;128(5):500-3; discussion 503-4.
65. Pescatori M, Mattana C, Castagneto M. Clinical and functional results after restorative proctocolectomy. Br J Surg 1988;75(4):321-4.
66. Romanos J, Samarasekera DN, Stebbing JF, Jewell DP, Kettlewell MG, Mortensen NJ. Outcome of 200 restorative proctocolectomy operations: the John Radcliffe Hospital experience. Br J Surg 1997;84(6):814-8.
67. Olsen KO, Joelsson M, Laurberg S, Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999;86(4):493-5.
68. Gullberg K, Stahlberg D, Liljeqvist L, Tribukait B, Reinholt FP, Veress B, et al. Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. Gastroenterology 1997;112(5):1487-92.
69. Lofberg R, Liljeqvist L, Lindquist K, Veress B, Reinholt FP, Tribukait B. Dysplasia and DNA aneuploidy in a pelvic pouch. Report of a case. Dis Colon Rectum 1991;34(3):280-3; discussion 283-4.
70. Rodriguez-Sanjuan JC, Polavieja MG, Naranjo A, Castillo J. Adenocarcinoma in an ileal pouch for ulcerative colitis [letter]. Dis Colon Rectum 1995;38(7):779-80.
71. Sequens R. Cancer in the anal canal (transitional zone) after restorative proctocolectomy with stapled ileal pouch-anal anastomosis. Int J Colorectal Dis 1997;12(4):254-5.
72. Stern H, Walfisch S, Mullen B, McLeod R, Cohen Z. Cancer in an ileoanal reservoir: A new late complication? Gut 1990;31(4):473-5.
73. Stein R, Lichtenstein GR. Complications of the ileoanal pouch. Seminars in Gastrointestinal Diseases 2000;11:2-9.
74. Thompson-Fawcett MW, Marcus V, Redston M, Cohen Z, McLeod RS. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. Gastroenterol 2001;121:275-81.
75. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 1983;14(11):931-68.
76. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343(8889):71-4.
77. Blackstone MO, Riddell RH, Rogers BH, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: An indication for colectomy. Gastroenterology 1981;80(2):366-74.
78. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: The predictive value of low-grade dysplasia. Gastroenterology 1992;103(2):431-8.
79. Brostrom O, Lofberg R, Ost A, Reichard H. Cancer surveillance of patients with longstanding ulcerative colitis: A clinical, endoscopical, and histological study. Gut 1986;27(12):1408-13.
80. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107(4):934-44.
81. Jones HW, Grogono J, Hoare AM. Surveillance in ulcerative colitis: Burdens and benefit. Gut 1988;29(3):325-31.
82. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci 1989;34(10):1536-41.
83. Manning AP, Bulgim OR, Dixon MF, Axon AT. Screening by colonoscopy for colonic epithelial dysplasia in inflammatory bowel disease. Gut 1987;28(11):1489-94.
84. Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991;100:1241-8.
85. Rozen P, Baratz M, Fefer F, Gilat T. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology 1995;108(5):1361-70.
86. Engelsgjerd M, Farraye F, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999;117:1288-94.
87. Rubin P, Friedman S, Harpaz N, Goldstein E, Weiser J, Schiller J, et al. Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295-300.
88. Fogt F, Alsaigh N. Polypoid dysplasias in ulcerative colitis and sporadic adenomas: Genetic approach to the differential diagnosis. Oncol Rep 1999;6:721-5.
89. Gyde S. Screening for colorectal cancer in ulcerative colitis: Dubious benefits and high costs. Gut 1990;31(10):1089-92.
90. Karlen P, Young E, Bronstom O, Lofberg R, Tribukait B, Ost A, et al. Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: Relation to dysplasia and DNA aneuploidy. Gastroenterology 1998;115:1395-404.
91. Jaramillo E, Watanabe M, Befrits R, et al. Small, flat colorectal neoplasia in long standing ulcerative colitis. Gastrointest Endosc 1996;44:15-22.
92. Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990;336(8711):357-9.
93. Fielding JF, Prior P, Waterhouse JA, Cooke WT. Malignancy in Crohn's disease. Scand J Gastroenterol 1972;7(1):3-7.
94. Fireman Z, Grossman A, Lilos P, Hacohen D, Barr Meir S, Rozen P, et al. Intestinal cancer in patients with Crohn's disease. A population study in central Israel. Scand J Gastroenterol 1989;24(3):346-50.
95. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut 1994;35(5):651-5.
96. Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH Jr. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 1981;48(12):2742-5.
97. Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN. Malignancy in Crohn's disease. Gut 1980;21(12):1024-9.
98. Kvist N, Jacobsen O, Norgaard P, Ockelmann HK, Kvist HK, Schou G, et al. Malignancy in Crohn's disease. Scand J Gastroenterol 1986;21:82-6.
99. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105(6):1716-23.
100. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. Crohn's disease and cancer. N Engl J Med 1973;289(21):1099-103.
101. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: Implications for carcinogenesis and prevention. Gut 1994;35(7):950-4.
102. Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120:820-8.
103. Hamilton SR. Colorectal carcinoma in patients with Crohn's disease. Gastroenterology 1985;89(2):398-407.
104. Bernstein CN. ALMs versus DALMs in ulcerative colitis: Polypectomy or colectomy? Gastroenterology 1999;117:1488-91.
105. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92(2):204-11.
106. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: An analysis of performance. Gastrointest Endosc 2000;51(2):123-8.
107. Bernstein CN, Weinstein WM, Levine DS, Shanahan F. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 1995;90(12):2106-14.
108. Greenstein AJ, Gennuso R, Sachar DB, Heimann T, Smith H, Janowitz HD, et al. Extra-intestinal cancers in inflammatory bowel disease. Cancer 1985;56(12):2914-21.
109. Farrell R, Kileen P, Mahmud N, O'Brien D, Kelleher D, Keeling P, et al. Increased risk of non-Hodgkin's lymphoma with immunomodulatory therapy in inflammatory bowel disease. Gastroenterology 1997;112(4):A969.
110. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67(7):2015-9.
111. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, et al. Crohn's disease and cancer: A population-based cohort study. Gastroenterology 1994;107(6):1675-9.
112. Loftus E, Sandborn W, Tremaine W, Harmsen W, Zinsmeister A. Risk of lymphoma in inflammatory bowel disease: A population-based estimate. Gastroenterology 1998;114(4):A1024.
113. Su CG, Stein RB, Lewis JD, Lichtenstein GR. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: Do risks outweigh benefits? Digest LiverDis 2000;32(6):518-31.
114. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after mmunosuppressive treatment. Am J Med 1985;78(1A):44-9.
115. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342(8886-8887):1514-6.
116. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis 1988;47(12):988-92.
117. Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989;47(2):293-6.
118. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347(8996):215-9.
119. Gelb A, Zalusky R. The use of azathiaprine and 6-mercaptopurine (6-MP) as immunosuppressive therapy in inflammatory bowel disease and its role in the etiology of lymphocytic lymphoma [letter]. Am J Gastroenterol 1983;78(5):316.
120. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91(9):1711-4.
121. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989;111(8):641-9.
122. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91(3):423-33.
123. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma. Gastroenterology 2000;118(6):1018-24.
124. Dayharsh GA, Loftus EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7.
125. Deleted in proof.
126. Korelitz BI. Carcinoma arising in crohn's disease fistulae: Another concern warranting another type of surveillance. Am J Gastroenterol 1999;94:2337-8.
127. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: A case-control study. Cancer 1998;82(5):822-6.
128. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-9.
129. Lennard-Jones JE, Morson BC, Ritchie JK, Williams CB. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet 1983;2(8342):149-52.